Isoflurane - Generic Drug Details

What are the generic drug sources for isoflurane and what is the scope of freedom to operate?

Isoflurane is the generic ingredient in two branded drugs marketed by Baxter Hlthcare, Halocarbon Prods, Hospira, Piramal Critical, Piramal Pharma, Shandong, and Watson Labs Inc, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

There are eight drug master file entries for isoflurane. Five suppliers are listed for this compound.

Summary for isoflurane

US Patents:	0
Tradenames:	2
Applicants:	7
NDAs:	7
Drug Master File Entries:	8
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	285
Patent Applications:	7,987
What excipients (inactive ingredients) are in isoflurane?	isoflurane excipients list
DailyMed Link:	isoflurane at DailyMed

Recent Clinical Trials for isoflurane

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Liaquat National Hospital & Medical College	PHASE1
Xijing Hospital	PHASE3
Ain Shams University	PHASE3

See all isoflurane clinical trials

Pharmacology for isoflurane

Drug Class	General Anesthetic
Physiological Effect	General Anesthesia

Medical Subject Heading (MeSH) Categories for isoflurane

Anesthetics, Inhalation

Anatomical Therapeutic Chemical (ATC) Classes for isoflurane

N01AB	Halogenated hydrocarbons
N01A	ANESTHETICS, GENERAL
N01	ANESTHETICS
N	Nervous system

US Patents and Regulatory Information for isoflurane

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shandong	ISOFLURANE	isoflurane	LIQUID;INHALATION	216527-001	Nov 4, 2025	AN	RX	No	No
Halocarbon Prods	ISOFLURANE	isoflurane	LIQUID;INHALATION	075225-001	Oct 20, 1999	AN	RX	No	No
Hospira	ISOFLURANE	isoflurane	LIQUID;INHALATION	074097-001	Jan 25, 1993		DISCN	No	No
Baxter Hlthcare	FORANE	isoflurane	LIQUID;INHALATION	017624-001	Approved Prior to Jan 1, 1982	AN	RX	Yes	Yes
Piramal Critical	ISOFLURANE	isoflurane	LIQUID;INHALATION	074416-001	Sep 30, 1994	AN	RX	No	No
Watson Labs Inc	ISOFLURANE	isoflurane	LIQUID;INHALATION	074393-001	May 12, 1995		DISCN	No	No

Expired US Patents for isoflurane

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	FORANE	isoflurane	LIQUID;INHALATION	017624-001	Approved Prior to Jan 1, 1982	3,535,388
Baxter Hlthcare	FORANE	isoflurane	LIQUID;INHALATION	017624-001	Approved Prior to Jan 1, 1982	3,535,425

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: Isoflurane

Last updated: July 28, 2025

Introduction

Isoflurane is a widely used inhalational anesthetic agent primarily employed during surgical procedures to induce and maintain anesthesia. Its unique pharmacologic profile, safety, and efficacy have cemented its role within the anesthetic landscape for decades. As the pharmaceutical industry evolves, understanding isoflurane’s market dynamics and financial trajectory offers vital insights into its current valuation, competitive positioning, and future outlook amidst shifting healthcare priorities.

Market Landscape and Key Drivers

Established Role and Market Penetration

Isoflurane’s longstanding presence in the global anesthetic market stems from its favorable profile, including rapid onset, controllable anesthesia depth, and relatively low incidence of side effects like nausea or cardiovascular depression. The drug’s extensive adoption has resulted in widespread utilization, especially in developed markets such as North America and Europe ([2]).

Competitive Environment

The anesthetic market is highly competitive, dominated by volatile players like Pfizer (Precedex), Sevoflurane by Maruho, and newer agents such as desflurane. Isoflurane faces ongoing competition from these agents, which offer benefits like faster recovery times or fewer environmental concerns. Nevertheless, its cost-effectiveness and proven safety keep it relevant, particularly in resource-constrained settings.

Regulatory and Safety Considerations

Isoflurane's market stability is underpinned by decades of clinical data, reinforced by regulatory approvals from agencies such as FDA and EMA. Recent concerns over environmental impact, particularly its contribution to greenhouse gases (e.g., potent global warming potential), have prompted regulatory scrutiny and could influence future use patterns ([3]).

Healthcare Infrastructure and Surgical Volume Trends

The global surge in elective surgeries, driven by aging populations and expanding healthcare infrastructure, has bolstered demand for inhalational anesthetics like isoflurane. According to WHO data, surgical volume increases correlate positively with anesthetic market growth, particularly in emerging economies that continue to ramp up healthcare services ([4]).

Market Dynamics Shaping Financial Trajectory

Demand Stability in Developed Markets

Historically, isoflurane has maintained consistent demand in developed countries due to familiarity, extensive clinician experience, and cost advantage. The stability is reinforced by the high procedural volume of general anesthesia, which remains essential for various surgeries.

Emerging Markets and Growth Opportunities

Growth corridors, especially in Asia-Pacific and Latin America, indicate increasing adoption of inhalational anesthetics, driven by economic development and expanding healthcare access. These regions represent promising revenue streams for established manufacturers and generic distributors alike.

Environmental Regulation Impact

Environmental concerns about the global warming potential of volatile anesthetic agents, including isoflurane, threaten future market stability. Entities such as the European Union have initiated measures to limit or regulate emissions, potentially affecting sales volumes and prompting industry investments in greener alternatives or mitigation technologies ([5]).

Innovations and Formulation Advancements

While no major reformulations of isoflurane currently exist, technological innovations in anesthetic delivery systems—such as low-flow systems or environmentally friendly anesthetic waste capture—may influence future use efficiency and cost margins, impacting profitability.

Financial Outlook and Revenue Projections

Current Revenue Streams

Estimates peg the global inhalational anesthetic market at approximately USD 950 million in 2022, with isoflurane constituting roughly 50%, predominantly supplied through generic versions ([6]). The dominant sales are concentrated in North America and Europe, with emerging markets contributing progressively.

Forecasted Growth Trajectory

Analysts project the inhalational anesthetic market to grow at a Compound Annual Growth Rate (CAGR) of about 4-6% over the next five years, driven by increasing surgical procedures globally. Isoflurane’s share is expected to remain stable due to its cost advantages and familiarity, although competition from newer agents may temper growth.

Potential revenue narrows due to regulatory pressure and environmental considerations, which could decline market share unless mitigative strategies are adopted. Nevertheless, existing formulations are likely to sustain steady revenues, especially where cost sensitivity prevails.

Impact of Patent Expirations and Generic Competition

Most isoflurane formulations are off-patent, fueling intense generic competition that compresses profit margins. Price erosion has been significant, with generic providers capturing larger market segments. This dynamic emphasizes volume sales over high-margin branding, aligning financial strategies towards cost leadership.

Strategic Considerations for Stakeholders

• Manufacturers must navigate environmental compliance costs, innovate delivery systems, and maintain production efficiencies.

• Healthcare providers focus on balancing operational costs with clinical efficacy, often favoring cost-effective agents such as isoflurane.

• Regulatory bodies influence market size through environmental and safety standards, potentially accelerated by climate change policies.

Conclusion

Isoflurane’s market dynamics are shaped by its entrenched clinical utility, global healthcare trends, regulatory pressures, and environmental considerations. Its financial trajectory appears stable within established markets, driven by consistent demand, while growth in emerging regions is promising. However, environmental concerns and competition from newer agents require ongoing adaptation from industry players to sustain profitability.

---

Key Takeaways

• Market stability stems from isoflurane’s proven safety and cost-effectiveness, especially in resource-limited settings.
• Growth prospects are primarily driven by increasing surgical volumes in emerging economies and continued demand in developed nations.
• Environmental regulations pose significant risks, prompting innovation in delivery technology and potentially alternative anesthetic agents.
• Generic competition leads to margin compression, emphasizing volume-driven sales strategies.
• Future industry success hinges on balancing environmental commitments with clinical and economic needs through technological innovation and strategic market positioning.

---

FAQs

1. How does environmental regulation impact the sale of isoflurane?
Environmental concerns regarding the greenhouse gas emissions of inhalational anesthetics have led regulators, especially in the EU, to develop stricter emission standards. This creates financial and operational challenges for manufacturers, potentially reducing market size unless greener alternatives or mitigation technologies are adopted.

2. What are the primary competitors to isoflurane in the anesthetic market?
Sevoflurane and desflurane are the main competitors, offering faster recovery profiles and lower environmental impacts. However, their higher costs and different safety profiles limit widespread replacement of isoflurane, especially in cost-sensitive markets.

3. Will patent expirations significantly affect isoflurane’s market share?
Since most formulations are off-patent, generic manufacturers dominate, leading to price competition that diminishes margins. This dynamic favors high-volume sales and intensifies price erosion.

4. Are there ongoing innovations that could alter isoflurane’s financial outlook?
Yes. Developments in delivery systems that reduce environmental impact and improve efficiency may extend isoflurane’s relevance. However, no significant reformulations are currently in commercial use.

5. How is demand for isoflurane expected to evolve over the next decade?
Demand is expected to remain stable in developed markets, with growth in emerging markets driven by increased surgical procedures. Environmental regulations and competition could moderate growth unless industry adapts innovatively.

---

Sources:
[1] Market Research Future, “Inhalational Anesthetics Market,” 2022
[2] Baxter, “Isoflurane: Clinical Pharmacology and Usage,” 2020
[3] European Medicines Agency, “Environmental Impact of Anesthetic Agents,” 2021
[4] WHO, “Global Surgical Volumes and Healthcare Infrastructure,” 2022
[5] Climate Policy Journal, “Regulatory Approaches to Anesthetic Gases,” 2022
[6] Grand View Research, “Inhalational Anesthetics Market Size and Forecast,” 2022